"Achroma Corp is excited to be able to launch our No Roadblocks Program with sponsorship support from AGTC,” said Bridget Vissari, President of Achroma Corp. ![]() ![]() “As AGTC diligently works to find a treatment using AAV-based gene therapies for achromatopsia, organizations like Achroma Corp provide an important service of improving quality of life for those living with an IRD.” “AGTC understands the unique challenges for those living with achromatopsia and is proud to be a sponsor of the No Roadblocks program and provide support to help these individuals gain independence through bioptic driving,” said Sue Washer, President and Chief Executive Officer of AGTC. Bioptic driving is a method of driving that uses a patient's general vision and intermittent spotting through a small telescopic system that improves the sharpness of the patient's vision. These filters are often essential to bioptic driving. There is no specific treatment for ACHM, although deep red tinted glasses or contact lenses can reduce symptoms of light sensitivity and daytime blindness. ACHM is associated with extremely poor visual acuity, extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. No Roadblocks is a program that funds tinted glasses or contact lenses, as well as bioptics, for individuals living with achromatopsia (ACHM), an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. 19, 2021 (GLOBE NEWSWIRE) - Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced it will be a sponsor of the Achroma Corp program, No Roadblocks. GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. Latham & Watkinshas acted as international lead counsel to Archroma in this transaction.- Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving. The team is co-led by Christoph Neeracher (partner, pictured left) and Luca Jagmetti (partner, pictured right) and includes Raphael Annasohn and Lukas Bründler (all m&a), Susanne Schreiber (tax), Markus Wang and Christine Schweikard (IP/IT/regulatory), Laura Widmer (employment), Corrado Rampini and Rocco Rigozzi (real estate) as well as Ruth Bloch-Riemer (pension). ![]() The combination with Textile Effects and its rich historical roots of Huntsman and Ciba Specialties will create a technology powerhouse that will include Archroma’s legacy heritages of Sandoz, Hoechst, Clariant, BASF and Dohmen who have been at the cutting edge of the textile industry for decades, and together will continue to serve customers for years to come.īoth Archroma and Textile Effects are founding members of Sustainable Chemistry for the Textile Industry (SCTI), an alliance of leading chemical companies that strives to empower the textile and leather industries to apply sustainable, state-of-the-art chemistry solutions that protect factory workers, local communities, consumers and the environment.īär & Karrerhas acted as Swiss legal advisor to Archroma in this transaction. Since its formation in 2013, through a series of mergers & acquisitions, as well as internal investments in R&D, manufacturing and service capabilities, Archroma has been building a comprehensive portfolio of solutions to serve the emerging needs of the textile industry. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close in the first half of 2023. Archroma, a leader in sustainable specialty chemicals and solutions and a portfolio company of U.S.-based private investment firm SK Capital Partners, has entered into a definitive agreement with Huntsman Corporation to acquire Huntsman’s Textile Effects division.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |